Korea / Special Situations, Clepsydra Capital

Sanghyun Park

I investigate special situations in Korea.

Korea / Special Situations

Samsung Biologics: Creation of a Holding Company to Split CDMO and Biosimilar Businesses

Clarifying a Few Points of Confusion Surrounding the Samsung Biologics Spin-Off

Getting a Clear Read on the Samsung Life Play to Flip into a Financial Holding Co

Intel Summary on Samsung Biologics Split and Samsung C&T’s Acquisition of Samsung Electronics Shares

Korea / Special Sits, Pairs, Index Rebalancing

Clepsydra Capital

Investigate special situations, pairs, and index rebalancing trades in Korea.

Event-Driven

<ul>
<li>Samsung C&amp;T’s holding ratio mainly hinges on its Samsung Biologics stake; Samsung Electronics’ 5% isn’t counted, and Samsung SDS is excluded since Samsung Electronics is its largest shareholder.</li>
<li>This ties to calls for Samsung’s governance overhaul, aiming for C&amp;T to avoid forced conversion while boosting control over Samsung Electronics via bold, more aggressive moves than expected.</li>
<li>Samsung C&amp;T will likely sell some Biologics shares around its in-kind contribution to Epis, timing sales based on post-listing price action.</li>
</ul>


Samsung C&amp;T’s holding ratio mainly hinges on its Samsung Biologics stake; Samsung Electronics’ 5% isn’t counted, and Samsung SDS is excluded since Samsung Electronics is its largest shareholder.
This ties to calls for Samsung’s governance overhaul, aiming for C&amp;T to avoid forced conversion while boosting control over Samsung Electronics via bold, more aggressive moves than expected.
Samsung C&amp;T will likely sell some Biologics shares around its in-kind contribution to Epis, timing sales based on post-listing price action.


Clearing Confusion on Samsung C&T’s Forced Holding Co Conversion: Key Trade Angle in Biologics Split